Abstract. The nuclear receptor PPAR (peroxisome proliferator-activated receptor) has three subtypes named a , d (b), and g that may act as receptors for a range of compounds including antihyperglycaemic drugs, insulin sensitizers, and non-steroidal anti-inflammatory drugs (NSAIDs). Although profiling of the subtype selectivity of the compounds for PPAR is indispensable to elucidate their pharmacological action, the absence of an appropriate transactivation assay for PPARd led us to develop a sensitive and reproducible method. We found that coexpression of PPARd, retinoid X receptor (RXR) a , and coactivators such as CBP and SRC-1 enhanced basal and agonist-dependent activation of PPAR responsive element (PPRE)-driven transcription by PPARd , rendering a PPRE-driven reporter assay reliable and sensitive. Utilizing this assay for PPARd , we re-evaluated the subtype selectivity of a variety of anti-inflammatory drugs for human PPAR. The PPAR agonists tested included two leukotriene (LT) D 4 antagonist, seven NSAIDs, and two anti-rheumatoid drugs. We found that a novel LTD 4 antagonist, FK011 ([2-(((2-(4-tert-butyl-1,3-thiazol-2-yl)-1-benzofuran-5-yl)oxy)methyl)phenyl]acetic acid), showed marked agonistic activity for PPARg. NSAIDs were classified into the following three groups: those showing no activity for all subtypes, those that were selective for PPARg such as indomethacin and diclofenac, and those showing agonistic activity for the d and g subtypes such as ibuprofen. These results will be important to studies on the molecular mechanisms of pharmacological actions of LTD 4 antagonists and NSAIDs.
Introduction
The transcription factor PPAR (peroxisome proliferator-activated receptor) is a member of the steroid receptor superfamily and has three subtypes named a , d (b), and g (1 -6). The g subtype has two isoforms, g1 and g2, the latter of which has additional 30 amino acid residues at the N terminus (7 -9) . The profiles of tissue distribution of mRNA for the three subtypes are quite different; namely, the mRNA for the b subtype is ubiquitously distributed (1) , whereas that for the g subtype is expressed highly selectively in adipocytes (7 -9) and that for the a subtype is expressed predominantly in several tissues including liver, heart and kidney (3, 6) . Although the physiological role of the d (b) subtype is yet unknown, evidence on the roles of the a and g subtypes has been accumulating. The a subtype is involved in the proliferation of peroxisomes and regulation of lipid metabolism, as indicated by the finding that it is a target of peroxisome proliferators, polyunsaturated fatty acids, eicosanoids, and hypolipidemic agents such as clofibrates (1, 10 -12) . The a subtype was also shown to shorten the duration of *Corresponding author. Present address for correspondence:
Biomarker Science Co., Ltd., 2-8 Honmachibashi, Chuo-ku, Osaka 540-0029, Japan FAX: +81-6-6943-1252 E-mail: kojo@biomarker.co.jp leukotriene (LT) B 4 -elicited inflammation by inducing the expression of catabolic enzymes for LTB 4 (13) . Meanwhile, the g subtype was recently elucidated to be a target of thiazolidinediones, insulin sensitizers, and further to promote the differentiation of adipocytes (7, 14 -16) . More recently, the g subtype was reported to induce differentiation of macrophages, to promote uptake of oxidized LDL by macrophages, and to inhibit production of cytokines such as interleukines 1 and 6 and tumor necrosis factor a in macrophages (17 -20) . These actions of the g subtype suggest other roles in inflammation and atherosclerosis. The different physiological roles and tissue distributions of the subtypes of PPAR prompted us to examine the subtype selectivity of existing and new PPAR agonists to evaluate their pharmacological effects. The subtype selectivity of PPAR agonists has been examined in quite a number of papers, but there have been few investigations of the selectivity to all three subtypes (6, 11 -14, 21 -23) .
The main reason for this situation is that a reproducible solid assay for PPARd (b) has been absent. Some of the investigations describing agonist activity for PPARd (b) used Gal4-PPARd-LBD (ligand binding domain) (12, 14, 21, 23) , but due to the artificial construct of components, there is some ambiguity as to how precisely this assay system reflects real transactivation. Meanwhile, we were faced with the problem that transactivation of a PPAR responsive element (PPRE)-driven reporter gene was attenuated by introduction of exogeneous PPARd (b) in the conditions reported by other investigators using an intact form of PPARd (b). In this report, we established a new reliable and sensitive assay for PPARd (b) and re-evaluated the PPAR subtype selectivity of two LTD 4 antagonists, seven non-steroidal antiinflammatory drugs (NSAIDs), two anti-rheumatoid drugs and four other miscellaneous drugs based on the transactivation assay of a PPRE-driven reporter including a newly developed assay for PPARd (b).
Materials and Methods

Reagents
Two LTD 4 antagonists, pranlukast and FK011 ([2- 
Plasmids
The cDNAs for human PPAR a , d , and g were synthesized using the polymerase chain reaction (PCR) with human liver cDNA for human PPARa , human heart cDNA for human PPARd (b), and human fat cell cDNA for human PPARg1 as templates. Retinoid X receptor (RXR) a expression plasmids were constructed by inserting a coding sequence of RXRa into the expression vector pcDNA3.1(+) (Invitrogen Corporation, Carlsbad, CA, USA). The cDNA for human RXRa was synthesized with human kidney cDNA as a template. The template cDNAs used were purchased from Clontech Laboratories Inc. (Palo Alto, CA, USA). The amplified cDNA fragments were cloned into pCRII (Invitrogen) and the nucleotide sequences of the cDNAs were determined by the dideoxy chain termination method using an automated laser fluorescent DNA sequencer (A.L.F.; Amersham Biosciences, Piscataway, NJ, USA). Multiple clones of each cDNA were sequenced and artifacts generated by the Taq polymeraase used in the PCR were revised by replacement of the specified region among the clones. The PPAR and RXRa expression plasmids were constructed by inserting each full-length cDNA at a multiple cloning site of the mammalian expression vector pCDM8, pcDNAI, or pcDNA3.1 (+) (Invitrogen). Coactivator expression plasmids pcDNA3.1-CBP and pcDNA3.1-SRC-1 were provided by Drs. T. Fujimura and I. Aramori of the Pharmacological Research Laboratories of Fujisawa Pharm. Co., Ltd. The human RXRg expression plasmid was purchased from Invitrogen.
The reporter gene plasmid pGVPPREluc-1 was constructed as follows. Three copies of a 33-bp PPRE identical to that of acyl CoA oxidase (24) were first cloned at the SalI site of pBLCAT-2 (25) to generate pBLPPRECAT-1. The luciferase reporter plasmid pGVPPRELuc was constructed by inserting the PPREcontaining fragment of pBLPPRECAT-1 at a multiple cloning site of PGV-P2 (Wako Pure Chemical Industries, Ltd., Osaka).
Gal4-PPARd(b) fusion expression plasmid for onehybrid assay was constructed as follows: Full-length PPARd (b) cDNA and PPARd (b)-LBD cDNA were prepared by PCR amplification using pCDM8-hPPARd as template, and the amplified cDNA was cloned into a multiple cloning site of the pBIND vector (Promega Corporation, Madison, WI, USA). The nucleotide sequence of each fusion expression plasmid was checked with an automated DNA sequencer. Reporter plasmid pG5luc for the one-hybrid assay was purchased from Promega.
Transient transfection assay
The African green monkey fibroblast cell line CV-1 was obtained from ATCC (Manassas, VA, USA) and maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco-BRL, Gaithersburg, MD, USA) supplemented with penicillin, streptomycin, and 10% heat inactivated fetal calf serum (HyClone, Logan, UT, USA). Cells were seeded at 2´10
5 per well of 6-well culture dishes and after overnight culture transiently transfected with 1 mg each of pGVPPRELuc luciferase reporter plasmid, PPAR expression plasmid, and RXRa expression plasmid together with the control Renilla luciferase expression plasmid RL-TK (Promega) using Lipofectamine 2000 (Gibco-BRL). Coactivator expression plasmid was also included when a transfection was performed for the PPARd assay. For the one-hybrid assay, cells were transfected with 1 m g each of pG5luc reporter plasmid and Gal4-PPARd fusion expression plasmid with RL-TK control plasmid. Cells were harvested 4 h after transfection and plated again at 1.6´10
4 per well onto 96-well plates. The drugs dissolved in dimethyl sulfoxide were added to the culture and the cells were incubated at 37°C for 24 h. After being washed with PBS(-), cells were lysed with PLB (passive lysis buffer) (Promega) and the lysates were used for reporter assays. Expression of the reporter was measured by the activity of firefly luciferase using the dual luciferase reporter assay system (Promega) and ARVO HTS 1420 multilabel counter (Amersham Biosciences) as a luminometer according to the instructions of the manufacturer. Firefly luciferase activity was corrected for transfection efficiency based on the activity of internal control Renilla luciferase.
Results
Examination of transactivation assay for PPARd (b)
We examined experimental conditions for a reproducible transactivation assay using intact PPARd to establish a method that excludes the possibility of obtaining improper results due to adoption of a onehybrid reporter assay utilizing an artificial fusion construct (Gal4-PPARd ) and also enables us to analyze the interaction between PPARd and a variety of transcription modulating factors. Firstly, we performed a one-hybrid assay using either Gal4-PPARd-LBD or Gal4-full length PPARd to identify agonists for human PPARd (Fig. 1) . In both assays, carbacyclin and bezafibrate were confirmed to have agonistic activity for PPARd . Hence, hereafter we used both compounds as reference agonists for PPARd . When we performed a transactivation assay using intact PPARd , we were faced with the problem that PPRE-driven reporter activity in the absence of exogeneous PPARd was not enhanced but unexpectedly attenuated by the introduction of exogeneous PPARd (Fig. 2) . The background activity and bezafibrate-induced transactivation in the absence of exogeneous PPARd were supposed to derive from endogenous PPAR in host cells. We then turned to searching for factors to complement PPARd and to enhance transactivation to a level exceeding that of the background. The introduction of exogeneous RXRg, a coreceptor of PPARs, was first tested but this did not enhance but rather attenuated PPRE-driven reporter activity (Fig. 2) . Next, we examined the effect of exogenous coactivators of the steroid receptor superfamily, CBP (26) and SRC-1 (27) , on the transactivation by PPARd . Neither coactivator alone affected the transactivation by PPARd , but together with RXRa , they not only increased markedly the basal transactivation activity but also enhanced the carbacyclin-induced response (Fig. 3) . To exclude the possibility that this enhancing effect resulted not from the activation by endogenous PPARs, we examined the effect of a combination of coactivators and RXRa on the transactivation by endogenous PPARs (Fig. 4) . The combination of exogenous coactivators and RXRa changed little the transactivation by endogeous PPARs; and thus, it was concluded that a reproducible and highly sensitive PPRE-driven reporter assay for PPARd was realized by combined use of exogenous PPARd , RXR, and a coactivator such as CBP or SRC-1.
Subtype selectivity of a wide range of anti-inflammatory drugs for human PPAR Our newly developed assay for PPARd enabled us to profile the agonistic activity of compounds for all subtypes of PPAR. Seven NSAIDs, two anti-rheumatoid drugs, two LTD 4 antagonists, and four other miscellaneous drugs were chosen for profiling since there are only few investigations dealing with the subtype selectivity of anti-inflammatory and anti-allergic drugs for human PPARs, although recent studies clarified the involvement of PPARs in inflammatory processes (13, 17 -20, 28 -30) . Transactivation of PPRE-driven luciferase transcription by PPRAa and g was performed by transfection by combination of RXRa and PPARa/ g, and that by PPARd was carried out via transfection of a combination of PPARd , RXRa , and CBP. 2 . Effect of RXRg on transactivation by PPARd . CV-1 cells were transiently transfected with 1 mg each of the pGVPPRELuc reporter plasmid alone; with pGVPPRELuc and expression plasmid pCDM8-hPPARd; or with pGVPPRELuc, pCDM8-hPPARd, and pcDNA3.1-hRXRa1 together with internal control RL-TK plasmid. Transfected cells were treated with the indicated concentrations of bezafibrate and cell extracts were subsequently assayed for luciferase activity. Details of transfection and the luciferase assay were described in the text. Results are shown as the mean of assays performed in triplicate and error bars represent the S.E.M. Fig. 3 . Coexpression of PPARd, RXRa, and coactivators stimulates transactivation by PPARd . CV-1 cells were transiently transfected as described in the legend of Fig. 2 except that coactivator expression plasmid pcDNA3.1-CBP or pcDNA3.1-SRC-1 was also co-transfected when indicated. Transfected cells were treated with the indicated concentrations of carbacyclin and cell extracts were subsequently assayed for luciferase activity. Details of transfection and the luciferase assay were described in the text. Results are shown as the mean of assays performed in triplicate and error bars represent the S.E.M.
We chose arachidonic acid and LTB 4 as natural ligands and also carbaprostacyclin, not a natural substance but a stable alternative for prostacyclin (PGI 2 ). Arachidonic acid was shown to initiate the transactivation of PPRE-driven luciferase activity by all PPAR subtypes, with a fold-increase of 1.7, 2.1, and 2.3 for PPARa , d , and g, respectively (Fig. 5) . Since LTB 4 was not examined at concentrations of more than 10 -6 M, its most agonistic activity was not observed, but LTB 4 definitely increased transactivation by PPARg with a fold-increase of 1.37 at 10 -6 M (Fig. 5) . Carbaprostacyclin activated transactivation by all subtypes with fold increase of 1.44, 4.37, and 3.03 for PPARa , d , and g, respectively (Fig. 5) . Since fibrates are well-known as agonists for PPARa , bezafibrate was selected as a reference PPARa agonist. Bezafibrate was confirmed to be a potent agonist for PPARa using our assay, but it was also shown to have agonsit activity for PPARd and g, although its potency was not high (Fig. 5) .
Since LTB 4 was reported to be an agonist for PPARs, we were interested in whether recently developed LTD 4 antagonists such as pranlukast (31) and FK011 have any agonistic activity for PPARs. Surprisingly, FK011 showed marked agonistic activity for PPARg with a fold-increase of 1.50 at 10 -6 M and 2.35 at 10 -5 M (Fig. 5) . Pranlukast was also shown to be an agonist for PPARg, although its potency appeared to be two orders of magnitude less than that of FK011 (Fig. 5) .
Among the seven NSAIDs and two anti-rheumatoid drugs examined, aspirin, acetoaminophen, auranofin, D-penicillamine, tiaramide, and piroxicam showed no agonistic activity for any subtype of PPAR (Fig. 6 ). Indomethacin and diclofenac showed selective agonistic activity for PPARg (Fig. 6) . The fold-increase of transactivation caused by indomethacin was 1.90 at 10 -5 M and 2.59 at 10 -4 M, while that by diclofenac was 1.54 at 10 -5 M and 1.93 at 10 -4 M. Different from the other NSAIDs, ibuprofen exerted agonistic activity for both PPARd and PPARg with a fold-increase of 2.11 and 2.22 at 10 -4 M, respectively (Fig. 6 ).
Discussion
A number of reports have been published on the agonistic activity of pharmacological agents including anti-inflammatory drugs for PPAR (28, 29) ; however, no comprehensive systematic study of the subtype selectivity of such agents has been performed. This status and the recent studies clarifying the involvement of PPARa and PPARg in inflammatory processes (13, 17 -20, 30) prompted us to re-evaluate the agonistic profiles of antiinflammatory and anti-allergic agents for PPAR. Such an investigation would provide basic information on the molecular mechanism of their pharmacological actions.
To reveal the agonistic profiles of the anti-inflammatory agents and anti-allergic agents, we first established an assay for transactivation of PPRE-driven luciferase transcription by PPARd , the absence of which has made it difficult to clarify the overall profile of agonistic activity of agents for PPAR. In place of an assay using full-length PPARd and a PPRE-driven reporter, one-hybrid reporter assays utilizing Gal4-PPARd have been sometimes employed, but this type of assay raises the following problems: 1) the possibility of obtaining improper results could not been absolutely excluded because it is an artificial construct and 2) it is less desirable to analyze the interaction between PPARd and a variety of transcription modulating factors than an assay using intact PPARd . Under the conditions described by other investigators for the transactivation of PPRE-driven reporter transcription by PPARd (6, 11, 13, 22) , we could not observe more transactivation beyond that in the absence of PPARd even when an agonist was added. During the preparation of this manuscript, two papers appeared reporting that PPARd is a potent inhibitor of ligand-induced transcriptional activity of PPARa and PPARg and that this inhibition is achieved by the binding of PPARd to a PPRE and the association of nonliganded PPARd with corepressors such as SMRT and NcoR (32, 33) . According to this finding, the observation mentioned above can be explained as follows. The introduction of exogenous PPARd represses the transactivation of PPRE-driven luciferase transcription by endogenous PPARa and PPARg. The addition of an agonist reverses this repression by PPARd but the rate of increase is marginal. However, PPARd -dependent transactivation is markedly enhanced by the co-expression of PPARd , RXRa , and coactivators such as CBP and SRC-1. Thus, this novel assay for PPARd is quite sensitive and reliable for detecting the agonistic activity of compounds.
On profiling the agonistic activity of anti-inflammatory and anti-allergic drugs for PPAR, we found for the first time that LTD 4 antagonists such as pranlukast and FK011 are selective agonists for PPARg. This raises the question of whether additional anti-allergic action may be caused by the agonistic activity of LTD 4 antagonists for PPARg.
A few papers have described agonistic activity of NSAIDs for PPARa and PPARg (28, 29) , but not for PPARd . We revealed that the subtype selectivity for PPAR leads to the classification of NSAIDs into three groups. The first group including aspirin, acetoaminophen, tiaramide, and piroxicam showed no agonistic activity for any subtype of PPAR. The second group including indomethacin and diclofenac showed high selectivity for the g subtype. The last group, ibuprofen, exerted agonistic activity for both PPARd and PPARg. Other investigators reported that a few NSAIDs including ibuprofen also have agonistic activity for PPARa (28, 29) . In spite of the fact that we could detect agonistic activity for PPARa by reference compounds including bezafibrate, arachidonic acid, and carbaprostacyclin using our assay, we could not find agonistic activity of NSAIDs for PPARa . The reason for this discrepancy between our data and other's results remains unclear. One possible explanation is that our assay differs considerably from the others' assays. While we adopted co-expression of the intact form of PPARa and RXRa , one of the other groups used PPARa alone while the other adopted a one-hybrid assay using Gal4-PPARa -LBD. Moreover, we normalized PPRE-driven firefly luciferase activity using internal control Renilla luciferase activity, whereas the other groups did not correct their data using an internal control. Furthermore, it should be noted that the two groups presented contradictory results on the agonistic activity of indomethacin for PPARa; one showed solid agonistic activity, while the other showed no activity despite using the same cell line as a host. Meanwhile, we could demonstrate for the first time that ibuprofen has agonistic activity for PPARd by using an assay for PPARd established in this study.
Recently, a considerable number of reports have been published describing the anti-inflammatory effects of PPARa and PPARg (13, 17 -20, 34, 35) . Furthermore, all three subtypes of PPAR have been elucidated to be involved in the apoptosis of a variety of cells including monocytes, which would be closely related to their antiinflammatory effect (36 -41) . Whether the agonistic activity of NSAIDs and LTD 4 antagonists contributes to their anti-inflammatory and anti-allergic actions and whether the different profiles of PPAR subtype selectivity among these compounds results in differences of pharmacological action still remains entirely unsolved. The results described in this report will provide important clues as to the molecular mechanisms of the pharmacological actions of NSAIDs and LTD 4 antagonists.
